{"id":740129,"date":"2023-03-15T03:04:01","date_gmt":"2023-03-15T07:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/"},"modified":"2023-03-15T03:04:01","modified_gmt":"2023-03-15T07:04:01","slug":"mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/","title":{"rendered":"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany"},"content":{"rendered":"<h2>\nLabor Staber to actively market and sell ColoAlert to its physician and patient network.<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BERKELEY, Calif. and MAINZ, Germany, March  15, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qh1_Ze7XR4VjQOTg0YdS33GumWBbpm29BLJMf2PsF9gLQ5O_7tu-WK40CNqwI0LzC9vydXEAst8W5nm2do2pzg==\" rel=\"nofollow noopener\" target=\"_blank\">Mainz Biomed NV<\/a> (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber &amp; Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.\u00a0<\/p>\n<p>\u201cAt Mainz, we are on a mission to save lives through the early detection of CRC \u2013 the third most common cancer globally \u2013 by increasing consumer access to affordable and reliable CRC screening tests like ColoAlert,\u201d said Guido Baechler, Chief Executive Officer of Mainz Biomed. \u201cWe continue to build mutually beneficial partnerships with diagnostic labs such as Labor Staber, as we have found putting our PCR testing kits in the hands of highly professional laboratory networks to be a much more effective business model than the traditional methodology of operating testing at a single facility.\u201d\u00a0<\/p>\n<p>With more than 800 employees, including almost 100 medical specialists, biologists, chemists, and other academics from a wide variety of disciplines, Labor Staber offers a broad range of state-of-the-art medical diagnostics and services from a single source. Under the terms of this agreement, ColoAlert will now be marketed through Labor Staber\u2019s extensive network of physicians and laboratories.<\/p>\n<p>\u201cOur labs combine regional character and collegiality with the organizational competence of a Germany-wide active laboratory group,\u201d said Dr. Thomas Kellerer, Head of Molecular Biology at Labor Staber. \u201cWe look forward to working with Mainz as we share the same passion \u2013 to improve patients\u2019 lives by using the most advanced analysis methods and equipment, as well as the highest quality standards, in all of our medical diagnostics.\u201d\u00a0<\/p>\n<p>\n        <strong>About ColoAlert<\/strong>\u00a0<br \/>ColoAlert, Mainz Biomed\u2019s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P_pVIjH7VzAu9-XZBBqcMujm7heY4OVoCK9YKlUNF8zc6pk-DNb3vwu1xFk6ZRBb0-FNdJN_Xbh2YR_Q6sqJyjIe-NzfWCDLKjVOVrnuTp72nZvsG-H5bs6WwMpy9TaY\" rel=\"nofollow noopener\" target=\"_blank\">Gies et al., 2018<\/a>). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial \u2018ReconAAsense\u2019. Once approved in the US, the Company\u2019s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.\u00a0<\/p>\n<p>\n        <strong>About Colorectal Cancer<\/strong>\u00a0<br \/>Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.\u00a0<\/p>\n<p>\n        <strong>About Mainz Biomed NV<\/strong>\u00a0<br \/>Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company\u2019s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed\u2019s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A93iT5zrCR1sb2dqN-rDUX0QkeaEFWUUHuK3xNGUcHIxj25c3DTmIBbrJERuozLJF50l_Qh2gFb5KXkhtPgjDA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>mainzbiomed.com<\/u><\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Eeqc9qS7tpsNnaUsseMw2SW-D4Wa3kveJfMW8zuQ3iBFkwt6lgUUb4jwtcHtFjgC0QVSl444H9iiXiIwpWr-zvJKWngzdkImkWpihp1Pk8Ts8xD-H5aJMrFSKew03JSK\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Reo1sDmJQIhK33L-Wh9TLsBk99rP-BxxpBBO2Frz9bGtiqeKNrAZNk2-vhU2dE2Z5jBogz8BqFwatjfquhD82g==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kib1WC1O4J69Z43BSKIYtQ8Iffl8r-h7IWC2g1rZI1OpIzneF7H80Epk_KqVSUkdz-_4SqKMslM0Chkk-_RpGQM0EHKEGcsevFQds3Tyl68=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Facebook<\/u><\/a>.\u00a0\u00a0<\/p>\n<p>\n        <strong>For media inquiries, please contact press@mainzbiomed.com<\/strong><br \/>\n        <br \/>In Europe:<\/p>\n<p>MC Services AG<br \/>Anne Hennecke\/Caroline Bergmann<br \/>+49 211 529252 20<br \/>mainzbiomed@mc-services.eu<\/p>\n<p>In the US:<\/p>\n<p>Spectrum Science<br \/>Melissa Laverty\/Valerie Enes<br \/>+1 540 272 6465<br \/>mainz@spectrumscience.com<\/p>\n<p>\n        <strong>For investor inquiries, please contact info@mainzbiomed.com<\/strong>\n      <\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201coutlook\u201d, and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company\u2019s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by the Company. Additional information concerning these and other factors that may impact the Company\u2019s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Company\u2019s SEC filings are available publicly on the SEC\u2019s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Njk5MzIwMzQtNjE5Ni00YjgyLWJmMWUtMWFmZDYyOWNlZDUwLTEyMzU2NDI=\/tiny\/Mainz-BioMed-NV.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber &amp; Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.\u00a0 \u201cAt Mainz, we are on a mission to save lives through the early &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740129","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber &amp; Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.\u00a0 \u201cAt Mainz, we are on a mission to save lives through the early &hellip; Continue reading &quot;Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T07:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany\",\"datePublished\":\"2023-03-15T07:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/\"},\"wordCount\":1028,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/\",\"name\":\"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==\",\"datePublished\":\"2023-03-15T07:04:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/","og_locale":"en_US","og_type":"article","og_title":"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany - Market Newsdesk","og_description":"Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber &amp; Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.\u00a0 \u201cAt Mainz, we are on a mission to save lives through the early &hellip; Continue reading \"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-15T07:04:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany","datePublished":"2023-03-15T07:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/"},"wordCount":1028,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/","name":"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==","datePublished":"2023-03-15T07:04:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5Nzg3MyM0MDE1MDg3MTMjMjIyNDA4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-labor-staber-to-expand-coloalert-commercialization-in-germany\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740129"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740129\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}